Prothena Co. plc (NASDAQ:PRTA) Shares Sold by TD Asset Management Inc

TD Asset Management Inc cut its holdings in shares of Prothena Co. plc (NASDAQ:PRTAFree Report) by 15.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 146,538 shares of the biotechnology company’s stock after selling 26,144 shares during the period. TD Asset Management Inc owned approximately 0.27% of Prothena worth $5,325,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Oppenheimer & Co. Inc. raised its holdings in Prothena by 3.9% during the third quarter. Oppenheimer & Co. Inc. now owns 7,908 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 295 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in Prothena by 0.6% during the fourth quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company’s stock worth $4,570,000 after purchasing an additional 741 shares in the last quarter. Alps Advisors Inc. raised its holdings in Prothena by 1.9% during the third quarter. Alps Advisors Inc. now owns 39,524 shares of the biotechnology company’s stock worth $1,907,000 after purchasing an additional 748 shares in the last quarter. Swiss National Bank raised its holdings in Prothena by 1.3% during the third quarter. Swiss National Bank now owns 87,000 shares of the biotechnology company’s stock worth $4,198,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in Prothena during the third quarter worth approximately $74,000. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Prothena Stock Performance

Prothena stock opened at $22.45 on Thursday. The company’s fifty day simple moving average is $22.07 and its 200-day simple moving average is $28.49. Prothena Co. plc has a 12 month low of $19.52 and a 12 month high of $77.13.

Prothena (NASDAQ:PRTAGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.21) by ($0.13). Prothena had a negative net margin of 193.17% and a negative return on equity of 30.48%. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $3.75 million. During the same quarter in the prior year, the firm earned ($0.89) earnings per share. On average, analysts forecast that Prothena Co. plc will post -4.69 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on PRTA shares. HC Wainwright dropped their target price on Prothena from $90.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. StockNews.com cut Prothena from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a report on Wednesday, April 10th. Oppenheimer dropped their price target on Prothena from $98.00 to $80.00 and set an “outperform” rating on the stock in a report on Tuesday, February 20th. Finally, JMP Securities dropped their price target on Prothena from $85.00 to $83.00 and set a “market outperform” rating on the stock in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $67.00.

Check Out Our Latest Report on PRTA

About Prothena

(Free Report)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Further Reading

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. plc (NASDAQ:PRTAFree Report).

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.